NASDAQ$APLT
Applied Therapeutics Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Reported positive data in both the Galactosemia pediatric study and pilot SORD Deficiency study, highlighting execution across programs and expansion into additional indications with AT-007.
Applied Therapeutics announced positive data from studies in Galactosemia and SORD Deficiency, and is preparing for a commercial launch in Galactosemia in 2022 and a registrational study in SORD later in 2021.
- Announced positive data in the Galactosemia pediatric study.
- Reported positive data in the pilot SORD Deficiency study.
- Preparing for commercial launch in Galactosemia in 2022.
- Focused on launching registrational study in SORD later in 2021.
Headline financials
Revenue & EPS history
Applied Therapeutics · Revenue · Quarterly
$1M
Forward guidance
The company plans to initiate a registrational study in SORD by the end of 2021 and anticipates a commercial launch in Galactosemia in 2022.
Tailwinds
- Plan to initiate a registrational study in SORD by the end of 2021.
- Anticipated commercial launch in Galactosemia in 2022.
- AT-007 has the potential to be the first disease-modifying therapy for SORD Deficiency.
- Data from clinical trials will support future development of product candidates.
- Likelihood of obtaining regulatory approval of product candidates.
Headwinds
- Plans to develop and commercialize product candidates.
- The initiation, timing, progress and results of current and future preclinical studies and clinical trials and research and development programs.
- Ability to take advantage of expedited regulatory pathways for any product candidates.
- Estimates regarding expenses, future revenue, capital requirements and needs for additional financing.
- Ability to successfully acquire or license additional product candidates on reasonable terms.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports
-2.6%
Avg return
Earnings day
-9.9%
Avg return
5 days after
-14.9%
Avg return
30 days after
52%
14 / 27 earnings
Positive
+24.0%
Q1 2025
Best reaction
-71.6%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -71.6% | -68.9% | -77.9% | |
| Q2 2025 | +5.6% | +9.1% | -5.6% | |
| Q1 2025 | +24.0% | -22.5% | -26.9% | |
| Q4 2024 | +0.1% | +4.3% | +1.5% | |
| Q3 2024 | +4.6% | +2.7% | -86.8% | |
| Q2 2024 | +5.7% | -4.4% | -6.4% | |
| Q1 2024 | -6.8% | -1.9% | -1.3% | |
| Q4 2023 | +7.3% | +2.6% | -6.2% | |
| Q3 2023 | -12.1% | -10.8% | +34.6% | |
| Q2 2023 | -3.2% | -14.1% | +1.3% | |
| Q1 2023 | -3.6% | -7.3% | -10.9% | |
| Q4 2022 | -5.6% | -7.9% | +6.3% | |
| Q3 2022 | -0.2% | — | — | |
| Q2 2022 | +3.0% | — | — | |
| Q1 2022 | -1.7% | — | — | |
| Q4 2021 | -9.1% | — | — | |
| Q3 2021 | +1.6% | — | — | |
| Q2 2021 | +3.6% | — | — | |
| Q1 2021 | -2.2% | — | — | |
| Q4 2020 | +3.3% | — | — | |
| Q3 2020 | +5.9% | — | — | |
| Q2 2020 | +13.8% | — | — | |
| Q1 2020 | +3.3% | — | — | |
| Q4 2019 | -27.7% | — | — | |
| Q3 2019 | -7.5% | — | — | |
| Q2 2019 | +7.0% | — | — | |
| Q1 2019 | -6.7% | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro